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Background and purpose   Population-based registry data from 
the Nordic Arthroplasty Register Association (NARA) and from 
the National Joint Register of England and Wales have revealed 
that the outcome after hip resurfacing arthroplasty (HRA) is 
inferior to that of conventional total hip arthroplasty (THA). We 
analyzed the short-term survival of 4,401 HRAs in the Finnish 
Arthroplasty Register.
Methods   We compared the revision risk of the 4,401 HRAs 
from the Register to that of 48,409 THAs performed during the 
same time period. The median follow-up time was 3.5 (0–9) years 
for HRAs and 3.9 (0–9) years for THAs.
Results   There was no statistically significant difference in revi-
sion risk between HRAs and THAs (RR = 0.93, 95% CI: 0.78–
1.10). Female patients had about double the revision risk of male 
patients (RR = 2.0, CI: 1.4–2.7). Hospitals that had performed 
100 or more HRA procedures had a lower revision risk than 
those with less than 100 HRAs (RR = 0.6, CI: 0.4–0.9). Articu-
lar Surface Replacement (ASR, DePuy) had inferior outcome 
with higher revision risk than the Birmingham Hip Resurfacing 
implant (BHR, Smith & Nephew), the reference implant (RR = 
1.8, CI: 1.2–2.7).
Interpretation   We found that HRA had comparable short-
term survivorship to THA at a nationwide level. Implant design 
had an influence on revision rates. ASR had higher revision risk. 
Low hospital procedure volume worsened the outcome of HRA. 
Female patients had twice the revision risk of male patients. 

Good short-term results of using modern hip resurfacing 
devices have been reported from pioneering centers (Amstutz 
et al. 2004, Daniel et al. 2004). Recently, these results have 
been confirmed by independent studies (Hing et al. 2007a, 
Heilpern et al. 2008, Steffen et al. 2008, Khan et al. 2009). 
However, there have been a variety of early complications 
of HRA, such as femoral neck fracture, aseptic loosening of 
the femoral component, and metallosis of the hip joint with 
soft-tissue necrosis (Shimmin et al. 2005, Keegan et al. 2007, 
Grammatopolous et al. 2009, Ollivere et al. 2009). Registry 
data have revealed that the early revision rate of HRA is higher 
than that of THA (Australian Orthopaedic Association, Johan-
son et al. 2010). Furthermore, conventional stems can nowa-
days be used with a large metal-on-metal (MoM) articulation 
similar to that in HRA. We examined the early outcome of 
HRA and compared it to that of THA using data in the Finnish 
Arthroplasty Register. 
Patients and methods
The Finnish Arthroplasty Register
Since 1980, the Finnish Arthroplasty Register has been col-
lecting information on total hip replacements (Paavolainen et 
al. 1991). Healthcare authorities, institutions, and orthopedic 
units are obliged to provide the National Institute for Health 
and Welfare with information essential for maintenance of the 
register. Since 1995, the data in the register have been com-
pared with those of hospital discharge registries at regular 
intervals. Currently, 98% of implantations are recorded. 
Study population and inclusion criteria
During the study period (2001–2009), 48,409 primary THRs 
and 4,401 primary HRAs were performed in Finland for pri-
mary or secondary osteoarthritis. To reduce the skew in the 
demographic distribution between patients operated with 
HRA and those operated with THA, patients older than 85 
years of age were excluded (the oldest patient operated with 
HRA was 85 years old). Also, those patients with another 
diagnosis (including fractures and avascular necrosis of the 
femoral head) or rheumatoid arthritis were excluded. Only 208  Acta Orthopaedica 2012; 83 (3): 207–213
HRA designs used in more than 90 operations during the 
study period and with more than 20 hips at risk at 5 years were 
included. These criteria permitted the inclusion of 6 HRA 
designs. 
Statistics
Kaplan-Meier survival analysis was used to calculate the sur-
vival probabilities of implants with 95% confidence interval 
(95% CI). These survival data were compared using the log-
rank test. Patients who died or left Finland during the follow-
up period were censored at that point. Adjusted revision rates 
were calculated using Cox multiple regression analysis. The 
proportional hazards assumption was controlled for by visual 
inspection of the Cox curves. Inclusion of bilateral cases in a 
survival analysis violates the basic assumption that all cases 
are independent. However, several reports have shown that the 
effect of including bilateral cases in studies of hip and knee 
joint prosthesis survival is negligible (Robertsson and Rans-
tam 2003, Lie et al. 2004). We therefore included all avail-
able cases to maximize statistical power. Relative risk (RR) 
estimates were calculated and are presented with 95% CI. The 
level of significance was 5%. 
Hip resurfacing vs. conventional implant design
The survival rate for HRA was compared to the survival rate of 
48,409 THAs performed for similar patients during the same 
time period, with adjustment for age at surgery, sex, operated 
side, and diagnosis, using Cox multiple regression (Table 1). 
In addition, stratified analyses were performed for males and 
females aged < 55 or ≥ 55 years. In these sub-analyses by age 
and sex, revision risk for HRA was compared to revision risk 
for all THAs and separately to revision risk for all cemented 
THAs performed for similar patients during the same time 
period. 
The hip resurfacing group 
The HRA group was further analyzed with regard to the influ-
ence of age at surgery, sex, operated side, diagnosis, and 
implant design on the risk of revision. The 6 most commonly 
used implant designs were studied (ASR, DePuy; BHR, Smith 
and Nephew; Durom, Zimmer; ReCap, Biomet; Conserve 
Plus, Wright Medical; and Cormet, Corin Medical) (Table 2), 
resulting in a study group of 4,401 hips with 159 revisions. 
Information about femoral head diameter was available in 
all cases. To investigate correlation with sex, femoral head 
diameter (classified as ≤ 44 mm, 45–49 mm, 50–54 mm, and   
≥55 mm) was added in separate evaluations. This is the same 
diameter classification as in the Australian Registry and the 
NARA report (Australian Orthopaedic Association, Johanson 
et al. 2010). 
Revisions were linked to the primary operation by using 
the patient’s personal identification number. The endpoint 
for survival was defined as revision when either one compo-
nent (including the femoral head) or the whole implant was 
removed or exchanged. Revision for any reason, for aseptic 
loosening, for dislocation, for infection, and for periprosthetic 
fracture each served separately as an endpoint. In 13 revi-
sions, the recorded indication for revision was “other reason”. 
Kaplan-Meier survival data were used to construct the survival 
probabilities of implants. These survival data were compared 
using the log-rank test. Patients who died or left Finland 
during the follow-up period were censored at that point. The 
Cox multiple regression model was used to study differences 
between groups and to adjust for potential confounding fac-
tors. The factors studied with the Cox model were the 6 hip 
resurfacing devices, age, sex, diagnosis, and hospital produc-
tion volume (≥ 100 or < 100 procedures). Effect of age on 
survivorship was also analyzed by dividing the patients into 2 
age groups: those under 55 years and those who were 55 years 
of age or older. Cox regression analyses provided estimates of 
survival probabilities and adjusted risk ratios for revision. Esti-
mates from the Cox analyses were used to construct adjusted 
survival curves at mean values of the risk factors. The Wald 
test was used to calculate p-values for data obtained from the 
Cox multiple regression analysis. Differences between groups 
were considered to be statistically significant if the p-values 
were less than 0.05 in a two-tailed test. The statistical analyses 
were conducted with PASW Statistics version 18. 
Table 2. HRA implant designs in 
the Finnish Arthroplasty Register, 
2001–2009
Implant design  %  n
BHR  42 1,856
ASR  23 995
ReCap  15 657
Conserve Plus  11  469
Durom  8 333
Cormet  2 91
Total  100 4,401
Table 1. Clinical details relating to HRAs and all THAs in 52,810 hips
 A  B  C  D  E  F  G  H  I  J
HRA    4,401  3.5 (0–8.7)  55 (9–85)  66  2001–2009  46  11 (1–104)  54  92
All THAs  48,409  3.9 (0–9.0)  68 (14–85)  42  2001–2009  78  69 (1–493)  57  94
 
A  Hip device 
B n 
C Mean follow-up (range) 
D Mean age (range) 
E  % Males 
F  Implanting period 
G No. of hospitals 
H Mean volume (range) of operations per hospital per year over the study period  
I  Operated side, % right 
J  Diagnosis, % primary osteoarthritisActa Orthopaedica 2012; 83 (3): 207–213  209
Results
Demographics and revisions
66% of the patients were male in the HRA group and 42% 
were male in the THA group. Mean age of HRA cases was 
55 (9–85) years and mean age of THA cases was 68 (14–85) 
years. Primary osteoarthritis was slightly more common in 
the THA group (94%) than in the HRA group (92%) (Table 
1). The HRA designs in the database are listed in Table 2. 
The main reason for revision of hip resurfacings was aseptic 
loosening of both components, whereas THAs were revised 
mainly because of dislocation. Unspecified reasons for revi-
sion (“other”) were recorded in 8% of the HRA revisions as 
compared to 5% of the THA revisions (Table 3). The 4-year 
unadjusted Kaplan-Meier survival was 96% (95% CI: 96–97) 
for both HRA and THA groups (Table 4).
Hip resurfacing vs. conventional implant designs—
overall results
There was no statistically significant difference in revision 
risk between HRAs and THAs (RR = 0.93, CI: 0.78–1.10; p = 
0.4) (Table 4, Figure 1) or between HRAs and all-cemented 
THAs (RR = 0.88, CI: 0.69–1.13; p = 0.3) (Table 5).
Hip resurfacing vs. conventional implant designs—
age and sex analysis 
There were no statistically significant differences in revi-
sion rates between HRAs and THAs or between HRAs and 
Table 3. Reasons for revision
A  B  C  D  E  F  G  H  I  J  K L
HRA    4,401  41 (26%)  26 (16%)  9 (6%)    10 (6%)      3 (2%)    24 (15%)  31 (19%)  2 (1%)  13 (8%)  159
THA  48,409  339 (19%)  195 (11%)  105 (6%)  199 (11%)  467 (27%)  133 (8%)  204 (12%)  20 (1%)  88 (5%)  1,750
Total  52,810   380 (20%)  221 (12%)  114 (6%)  209 (11%)  470 (25%)  157 (8%)  235 (12%)  22 (1%)  101 (5%)  1,909
             
A  Hip device 
B n 
C Aseptic loosening of both components 
D Aseptic loosening of the cup 
E  Aseptic loosening of the stem 
F Infection 
G Dislocation 
H Malposition 
I Fracture 
J  Implant breakage 
K  Other reason including local periprosthetic reactions such as metallosis associated with the metal-on-metal articulation. 
L All
Table 4. Survival of HRA and THA, the reference group. Endpoint was defined as revision of any component for any reason. Survival rates 
were obtained from the Kaplan-Meier analysis 
  A  B  C D  E  F  G H  I  J
BHR  1,856  4.4 (0.0–9.0)  1,253  97 (96–98)  668  96 (95–97)  111  95 (94–97)  0.72 (0.56–0.94)  0.02
ASR  995  3.1 (0.3–5.8)  440  95 (93–97)  39  92 (89–95)  –  –  1.28 (0.95–1.73)  0.1
ReCap  657  2.5 (0.4–5.7)  190  96 (94–98)  18  –  –  –  0.94 (0.59–1.48)  0.8
Conserve Plus  469  2.1 (0.4–4.7)  65  97 (95–98)  –  –  –  –  1.05 (0.61–1.83)  0.9
Durom  333  3.2 (0.2–5.1)  144  96 (94–98)  1  –  –  –  1.03 (0.60–1.74)  0.9
Corin (Cormet)  91  5.6 (0.2–7.6)  87  96 (92–100)  52  92 (86–99)  5  –  1.11 (0.50–2.48)  0.8
All HRAs  4,401  3.5 (0.0–9.0)  2,177  96 (96–97)  777  94 (93–95)  115  94 (93–95)  0.93 (0.78–1.10)  0.4
All THAs  48,409  3.9 (0.0–9.0)  25,482  96 (96–97)  14,607  95 (95–96)  5,601  94 (94–95)  1.0  –
A n 
B  Mean follow-up (years) 
C At risk, 4-year  
D 4-year survival (95% CI) 
E  At risk, 6-year
F  6-year survival (95% CI) 
G At risk, 8-year
H 8-year survival (95% CI) 
I  Adjusted risk ratio (RR) for revision (95% CI) from the Cox regression analysis (HRAs compared to THAs; with adjustment made for age, 
  sex, diagnosis, and implant).  
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all-cemented THAs in the subgroup analysis, by age and sex 
(Table 5). 
Hip resurfacing group: the 6 most commonly used 
designs
The mean overall follow-up for HRA designs and THAs is 
presented in Table 4. In Figure 2, the Cox-adjusted survival 
of HRA designs is compared to that of the cemented THA. 
Female patients had about twice the revision risk of male 
patients (RR = 1.98, CI: 1.44–2.71; p < 0.001) (Table 6). In 
repeated analysis also including the femoral head diameter, 
gender still had a statistically significant influence on revi-
sion rate. However, the femoral head diameter did not influ-
ence the revision rate (Table 7). Hospitals that had performed 
100 or more HRA procedures had a lower revision risk than 
those with less than 100 HRAs (RR = 0.61, CI: 0.41–0.88; p = 
0.009) (Table 6). 
When we compared the different HRA designs using BHR 
as a reference, ASR had a higher risk of revision than BHR 
(RR = 1.83, CI: 1.23–2.72; p = 0.003) (Table 6 and Figure 3). 
CI for the Durom, ReCap, Converse Plus, and Corin designs 
showed considerable overlap, and the analysis did not permit 
any ranking among them.
 
Discussion
We found that hip resurfacing arthroplasty had short-term 
survivorship comparable to that of total hip arthroplasty on a 
nationwide level. Implant design had an influence on revision 
Figure 1. Cox-adjusted survival curves for 4,401 
HRAs and 48,409 THAs. The endpoint was 
defined as revision for any reason. Adjustment 
was made for age at surgery, sex, operated side, 
and diagnosis. 
Figure 3. Cox-adjusted survival curves for 
six HRA designs (1,856 BHR, 995 ASR, 657 
ReCap, 469 Conserve Plus, 333 Durom, and 
91 Corin). The endpoint was defined as revi-
sion for any reason. Adjustment was made for 
age at surgery, sex, operated side, diagnosis, 
and femoral head diameter (categorized as ≤ 
44 mm, 45–49 mm, 50–54 mm, and ≥ 55 mm). 
Figure 2. Cox-adjusted survival curves for 
6 HRA designs (1,856 BHR, 995 ASR, 657 
ReCap, 469 Conserve Plus, 333 Durom, 
and 91 Corin) and 18,843 cemented THAs. 
The endpoint was defined as revision for 
any reason. Adjustment was made for age 
at surgery, sex, operated side, and diagno-
sis. 
Table 5. Age- and sex-stratified relative risk of revision. HRAs were 
compared to all THAs and to all cemented THAs implanted during 
the same period (2001–2009). Data are based on a Cox regression 
model adjusted for age, diagnosis, and type of implant 
  A  B C  D
Age ≤ 54 years        
  Males  0.83 (0.55–1.23)  0.3  0.55 (0.25–1.20)  0.1
  Females  1.05 (0.74–1.49)  0.8  0.96 (0.47–1.95)  0.9
Age ≥ 55 years       
  Males  0.74 (0.54–1.01)  0.06  0.73 (0.50–1.08)  0.1
  Females  1.38 (0.98–1.94)  0.06  1.36 (0.91–2.02)  0.1
A  Adjusted RR a of revision: HRA/all THAs (95% CI) 
B p-value 
C Adjusted RR a of revision: HRA/all cemented THAs (95%CI)
D p-value
a RR: See Table 4, footnote I.
Table 6. Relative risk of revision with 95% confidence interval (CI) in 
4,401 hip resurfacings (159 revisions). The data are based on a Cox 
regression model including age (< 54 or ≥ 55 years), sex, diagnosis, 
and the 6 most common HRA designs with BHR as reference
  RR  95% CI  p-value
BHR (reference)  1  – 
Corin  1.34 0.57–3.16  0.5
Converse Plus  1.60  0.88–2.91  0.1
Durom  1.58 0.86–2.91  0.1
ReCap  1.17 0.68–2.01  0.6
ASR  1.83 1.23–2.72  0.003
Female / Male  1.98  1.44–2.71  < 0.001
Age (< 55 / ≥55 years)  1.05  0.75–1.45  0.8
Secondary / primary OA  1.25  0.75–2.10  0.4
Hospital production volume: 
  ≥ 100 / < 100 procedures  0.61   0.42–0.89  0.009Acta Orthopaedica 2012; 83 (3): 207–213  211
rates, as did volume of hospital procedures. Female patients 
had twice the revision risk of male patients.
We acknowledge that the present study has methodologi-
cal shortcomings. By conducting a registry-based study, we 
were not able to compare the functional results between the 
groups. Nor did we perform any radiological analyses, which 
could have detected silent osteolysis, neck narrowing (Hing et 
al. 2007b), or adverse biological reactions linked to metal-on-
metal articulation (Shimmin et al. 2005, Keegan et al. 2007, 
Grammatopolous et al. 2009, Ollivere et al. 2009,). Patients in 
the HRA group had a lower mean age than patients in the THA 
group. There were also more male patients in the HRA group. 
These problems were adjusted for as far as possible by the use 
of regression models. In theory, of course, selection bias can 
only be avoided by conducting a randomized controlled trial. 
However, it has recently been pointed out that well-designed 
observational studies provide reliable information on treat-
ment effects, and the role of single, randomized controlled 
studies should not be overemphasized in clinical decisions 
(Benson and Hartz 2000, Concato et al. 2000). 
The follow-up time of 0–9 years was relatively short. The 
proportion of revisions that could be related to surgical and 
technical errors was probably high. With longer follow-
up, other reasons for revision—and especially those related 
to wear and toxic reaction caused by wear-related debris or 
release of metal—might be supposed to change the relative 
distribution of revisions results (Hing et al. 2007a, Heilpern et 
al. 2008, Steffen et al. 2008, Khan et al. 2009). Aseptic loosen-
ing of the cup was a relatively common finding in our study. 
Most of these cases are clear clinical entities with failure of 
osteointegration. These fixation failures are usually diagnosed 
during the first months after the index operation. However, 
some patients manage longer periods with moderate symptoms 
with a loose cup, until the position of the cup finally changes. 
It is still possible that some adverse reactions to metal debris 
(ARMDs) are falsely classified as aseptic loosening because 
of the lack of a specific question about ARMD in the Finn-
ish data collection form. Aseptic loosening of a cementless 
cup is indeed a short-term complication. In the long term, the 
osteointegrated cups do not become loose unless there is mas-
sive osteolysis caused by, for example, polyethylene debris. 
ARMD can cause massive soft tissue damage in the hip, but it 
is seldom the true reason for loosening. 
Revisions performed for dislocation are often complex 
operations. It is true that soft tissue problems seldom exist in 
the revisions for dislocation, in contrast to the situation with 
revisions for ARMD. However, most ARMD revisions in Fin-
land have—at least until now—been moderate, and the tech-
nical problems in these revisions have been solved using the 
same options as in other revisions. 
The total number of revisions was also relatively low, per-
mitting only a minimum of stratified analysis and increasing 
the sensitivity to random effects of single revision cases. Most 
of the good short-term results for hip resurfacing arthroplasty 
have been published from pioneering centers (Amstutz et al. 
2004, Daniel et al. 2004, Treacy et al. 2005). Recent indepen-
dent reports have confirmed these results (Hing et al. 2007a, 
Heilpern et al. 2008, Steffen et al. 2008, Khan et al. 2009). 
However, reports from national joint replacement registries 
have shown higher revision rates for hip surfacing than for 
conventional arthroplasty (Johanson et al. 2010, National 
Joint Registry for England and Wales (NJR England-Wales)). 
According to the Australian Arthroplasty Register, the cumu-
lative revision rate of HRAs for primary osteoarthritis in 9 
years was 7.2% (95% CI: 6.2–8.4) (Australian Orthopaedic 
Association). In our study, the 8-year survival for HRA was 
94% (93–95), which is similar to that published from Aus-
tralia. The adjusted risk ratio for revision, between HRA 
and THA, was similar in our study. In the subgroup analy-
ses by age and sex, there were no differences either between 
HRAs and cemented THAs. However, we found some sup-
port for the previous finding that especially elderly women 
with HRA have an increased risk of revision compared to 
those with conventional implants (Johanson et al. 2010). In 
the Nordic Arthroplasty Register Association (NARA) data-
base, there was also a higher revision risk in younger women 
with HRA than in those with cemented THA (Johanson et al. 
2010). The results of cemented implants in young patients 
in Finland have not been as good as in other Nordic coun-
tries (Mäkelä et al. 2011). On the other hand, the number 
of HRAs implanted in Finland is more than twice as high 
as that of HRAs implanted in the 3 other Nordic countries 
together. It is obvious that the amount of HRAs per surgeon 
has been higher in Finland than in other Nordic countries, 
which may partly explain the differences in results between 
previous studies and the current study. Furthermore, in our 
analysis, patients with aseptic necrosis were excluded. This 
may have had a positive affect on our results. However, it is 
also possible that the survival of the Finnish THA is poorer 
than those in Australia and in Scandinavia due to common 
usage of cementless implants and wear problems. The HRA 
Table 7. The same type of analysis as in Table 6 except that femoral 
head diameter (categorized as ≤ 44 mm, 45–49 mm, 50–54 mm, and 
≥ 55 mm) has been added, resulting in 4,401 resurfacings (159 revi-
sions) available for analysis a
  RR  95% CI  p-value
BHR (reference)  1  – 
ASR  1.73 1.14–2.61 0.01
Female / Male  1.87  1.19–2.92  0.006
Age (< 55 / ≥ 55 years)  1.00  0.72–1.38  1.0
Femoral head diameter
  ≤ 44 mm (reference)  1  – 
  45–49 mm  0.89  0.41–1.94  0.8
  50–54 mm  0.75  0.40–1.41  0.4
  ≥ 55 mm  0.65  0.38–1.12  0.1
a Only the results for BHR, ASR, age, sex, and femoral head diam-
eter are given to make the table easier to read.212  Acta Orthopaedica 2012; 83 (3): 207–213
there were 26 cases of aseptic loosening of the cup only (16%) 
and 9 cases of aseptic loosening of the stem only (6%). Alto-
gether, 76 of 159 HRA revisions (48%) in the Finnish register 
were performed for aseptic loosening. In clinical practice, one 
usually has to revise both components of the HRA because of 
bearing surface compatibility when the HRA cup is revised for 
early instability. Most of the early problems with aseptic loos-
ening in Finland are therefore probably due to unstable cups 
because of smooth coating (Durom) and difficult operative 
techniques. Isolated loose femoral components without frac-
ture were rare in the short term. In our analysis, patients with 
aseptic necrosis were excluded. This may have had a positive 
affect on our results of revisions performed for fractures. 
There were 3 revisions due to dislocation in the HRA group 
(0.07% of all HRAs) and 467 in the THA group (1.0% of all 
THAs). The relatively high dislocation rate of THA should not 
be forgotten when comparing different devices. Femoral neck 
fracture was the reason for revision in 19% of all revisions, 
which is less than in previous reports (Australian Orthopaedic 
Association, Johanson et al. 2010). 
A well-known disadvantage of a metal-on-metal articu-
lation is that it releases a large amount of very small metal 
(CoCr) particles and ions, which may lead to adverse biologi-
cal reactions, including local soft tissue toxicity, delayed type 
hypersensitivity reactions, osteolysis, and even risk of carci-
nogenesis (Keegan et al. 2007, Shimmin et al. 2005). Nowa-
days, HRA surgeons are familiar with HRA joint hydrops with 
milky sterile fluid, soft tissue necrosis, and pseudotumors. It 
is possible that there will be an increasing number of metal-
on-metal bearing surface revisions in the future. In the Finnish 
Arthroplasty Register notification form, bearing surface com-
plications are not asked separately. It is probable that some of 
these HRA meta-bearing complications are coded in the Finn-
ish register as revisions performed for “other reason”. How-
ever, there were only 13 HRA revisions for “other reason”. It 
may be that during the past few years, surgeons have not yet 
been as familiar with this metal bearing problem as they are 
today, and some of them may have described it as loosening 
or malposition. 
In conclusion, we found that HRA had a short-term sur-
vivorship comparable to that of THA at a nationwide level. 
Implant design had an influence on revision rate, as did hospi-
tal procedure volume. Female patients had a revision risk that 
was twice that of male patients. 
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Data analysis: KM, AE, and PP.
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survival data may look good when comparing them with 
those of poor THAs. 
The Australian, British, and Scandinavian registries have 
reported approximately twice the revision rate for women 
than for men (Australian Orthopaedic Association, National 
Joint Registry for England and Wales (NJR England-Wales), 
Johanson et al. 2010). However, based on data from the Aus-
tralian register, it has been stated that on adjusting for femoral 
head size, female sex no longer remained as an independent 
risk factor (Prosser et al. 2010). On the other hand, the NARA 
group found that femoral head diameter alone had no influence 
on early revision rate (Johanson et al. 2010). In our analysis 
of HRA, we also found that the revision rate for females was 
twice that for men. We could not find any reduced revision 
risk with increased femoral head diameter, which supports the 
results of the NARA group. 
We used a limit of 100 HRAs to separate low-volume hos-
pitals from high-volume hospitals. Information on operative 
volume per surgeon was not available. High hospital produc-
tion volume was associated with a reduced risk of revision. 
It seems reasonable that in Finland, hip resurfacings should 
be centralized to high-volume hospitals. HRAs had been per-
formed in 46 hospitals during the study period. 
6 designs were analyzed separately. The BHR device was 
the only implant that had a reduced risk of revision compared 
to THAs. The THAs included were the most commonly used 
brands during the study period in Finland. It is possible that 
some THA implants analyzed separately would have had 
higher survival than BHR. However, we wanted to compare 
BHR, the market leader, with the average THA. When the revi-
sion risk of other HRA models was compared to that of BHR, 
there were no statistically significant differences between 
implants—except for ASR, which had an increased risk of 
revision. These findings are consistent with results from the 
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